Korean J Dermatol.
2006 Aug;44(8):1007-1009.
A Case of Paronychia Occurring after Injection with Cetuximab (Erbitux(R), IMC-C225)
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea. mhlee@khmc.or.kr
- 2Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
Abstract
- We report a case of paronychia induced by cetuximab in a 43-year-old woman. Cetuximab is an antibody to the epidermal growth factor receptor, and has previously been shown to block the proliferation of various cancer cells. The patient had taken cetuximab for the treatment of metastatic rectal cancer. One month after the injection of cetuximab, the patient visited our clinic with painful periungal edema and erythema. The lesions partially improved after treatment with systemic and topical antibiotics. But, after discontinuing cetuximab, there was a significant decrease in the erythematous and edematous plaques. Three weeks later, she was asymptomatic and the lesions had resolved completely.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Acneiform Eruption Occurring after Injection of Cetuximab (Erbitux(R), IMC-C225)
- Two Cases of Acneiform Eruption Caused by Epidermal Growth Factor Receptor Inhibitors
- Clinical Features of the Cutaneous Adverse Events Induced by Combination Chemotherapy that Includes Cetuximab (Erbitux(R))
- Anti-epidermal growth factor receptor (EGFR) monoclonal antibody and DNA topoisomerase inhibitor reduce growth of salivary adenoid cystic carcinoma in a murine model
- Targeted Molecular Therapy in a Murine Model of Oral Squamous Cell Carcinoma with an Epidermal Growth Factor Receptor Inhibitor
